Jonathan Harris, Nutter McClennen & Fish LLP Photo

Jonathan A. Harris

Partner / Boston


Jonathan Harris is a business-minded patent attorney and MBA who helps life science companies understand and leverage IP. With over two decades of experience in every facet of patent practice, he has drafted complex patent licenses and international collaboration agreements, led IP diligence teams, prepared and prosecuted hundreds of patent applications, and served as first chair in patent infringement actions and post-grant proceedings collectively worth billions of dollars.

Jonathan’s experience in pharmaceuticals is particularly extensive. He has overseen IP due diligence and acted as lead trial counsel in multiple Paragraph IV matters on behalf of some of the world’s largest pharmaceutical companies. Having worked for innovators and generics alike, his unique and comprehensive background allows him to see around corners and position the patent estates of emergent life science companies to help raise capital and prepare for successful exit.

Jonathan is a partner in Nutter’s IP Department and a member of the firm’s Life Sciences group.

Notable Experience and Client Impact

Life Science Agreements

  • Patent licenses, collaborations, and commercial agreements: bioMerieux (clinical trial agreements); CoRISMA(medical device) in collaboration with China Grand; Insud Pharma (commercial agreements); Notable (cancer therapeutic) in worldwide collaboration with OncoHeroes; VeraDermics (derm therapeutics) in multiple collaborations and manufacturing agreements
  • University licenses: Cellinfinity (cancer therapeutic) with Ivy League university; Insud Pharma (diagnostic biomarkers)with Canadian university; LeptoX with Ivy League University; VeraDermics with Ivy League university

Patent Litigation

  • Analyze patent portfolios in preparation for Paragraph IV Notice Letters and litigation
  • Served as first chair trial counsel in numerous Paragraph IV patent actions: Cialis® ($2.3 billion annual sales); Lyrica® ($5.1 billion annual sales); Oxycontin® ($1.8 billion annual sales), Reclast®/Zometa® ($1.5 billion annual sales), and Ritalin®/Focalin® ($450 million annual sales)

IP Due Diligence

  • Assess patentability, conduct FTOs, and determine loss of exclusivity dates for multi-billion dollar commercial products and various Phase I-III assets
  • Focus on small and large molecule therapeutics and medical devices

News & Insights



  • The Best Lawyers in America, 2018-2024
  • IAM Patent 1000, 2021

Education & Admissions


University of Connecticut School of Law, J.D., cum laude
University of Connecticut School of Business, MBA, cum laude
Duke University, B.S., Biology


  • Connecticut
  • Massachusetts
  • U.S. Patent and Trademark Office

What Clients Say

  • “Adept at translating complex technical subjects into English.”
  • “Excellent patent analyst with an encyclopedic knowledge of Federal Circuit case law.”
  • “Great in the courtroom. Articulate and quick on his feet.”


  • The Best Lawyers in America, 2018-2024
  • IAM Patent 1000, 2021
Back to Page